Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Common Equity (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Common Equity data on record, last reported at $55.9 million in Q3 2025.

  • For Q3 2025, Common Equity rose 538.55% year-over-year to $55.9 million; the TTM value through Sep 2025 reached $55.9 million, up 538.55%, while the annual FY2024 figure was -$1.6 million, 203.59% down from the prior year.
  • Common Equity reached $55.9 million in Q3 2025 per FBIO's latest filing, up from $37.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $248.3 million in Q2 2021 and bottomed at -$15.9 million in Q2 2023.
  • Average Common Equity over 5 years is $79.4 million, with a median of $37.4 million recorded in 2025.
  • Peak YoY movement for Common Equity: plummeted 203.59% in 2024, then soared 925.15% in 2025.
  • A 5-year view of Common Equity shows it stood at $225.9 million in 2021, then crashed by 77.85% to $50.0 million in 2022, then tumbled by 96.83% to $1.6 million in 2023, then tumbled by 203.59% to -$1.6 million in 2024, then skyrocketed by 3497.93% to $55.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $55.9 million in Q3 2025, $37.4 million in Q2 2025, and $32.5 million in Q1 2025.